BirchBioMed Inc

Receive alerts
Unlisted (CA)
Market Cap:
52 weeks high
52 weeks low

In brief

BirchBioMed Inc., a clinical-stage biomedical company, focuses on the clinical evaluation, development, and commercialization of anti-scarring drugs, autoimmune therapeutics, and novel strategies for transplantation. Its products include FS2, a drug candidate for the treatment of scars on the molecular level; and AI-001, an oral drug administration, which is the combination of FS2 in conjunction with cell therapy for the treatment of autoimmune diseases. The company was founded in 2015 and is headquartered in King City, Canada.